TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

  title={TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy},
  author={Christopher Blake Rodell and Sean Philip Arlauckas and Michael F. Cuccarese and Christopher S. Garris and Ran Li and Maaz S. Ahmed and Rainer H. Kohler and Mikael J. Pittet and Ralph Weissleder},
  journal={Nature Biomedical Engineering},
Tumour-associated macrophages are abundant in many cancers, and often display an immune-suppressive M2-like phenotype that fosters tumour growth and promotes resistance to therapy. [] Key Result As a monotherapy, the administration of CDNP-R848 in multiple tumour models in mice altered the functional orientation of the tumour immune microenvironment towards an M1 phenotype, leading to controlled tumour growth and protecting the animals against tumour rechallenge.

TLR7/8 Agonist and SHP2 Inhibitor Loaded Nanoparticle Enhances Macrophage Immunotherapy Efficacy

The lipid nanoparticle‐mediated co‐delivery of a rational combination of TLR7/8 agonist and SHP2 inhibitor in the TAMs can enhance macrophage immunotherapy and show superior anti‐tumor efficacy than other treatments.

Systematic co-delivery of dual agonists to enhance cancer immunotherapy

It was concluded that in comparison to single agonist, the co-delivery of dual agonists, CpG and R848, can improve anti-tumor immune responses for cancer immunotherapy.

Development of Adamantane-Conjugated TLR7/8 Agonists for Supramolecular Delivery and Cancer Immunotherapy

The findings demonstrate the ability of strong nanoparticle-drug interactions to limit systemic toxicity of TLR agonists while simultaneously maintaining therapeutic efficacy.

Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer

targeted delivery of a c-MYC inhibitor to established M2 TAMs could reduce polarization toward an M2 phenotype in breast cancer models, and αvβ3-NP-mediated drug delivery of an MYC inhibitor can reduce protumor M2-like macrophages while preserving antitumorM1-likemacrophages in breast cancers.

The antitumoral activity of TLR7 ligands is corrupted by the microenvironment of pancreatic tumors

Molecular investigations revealed that Toll like receptor-7 agonists strongly increase the number of tumor-promoting macrophages to drive pancreatic tumorigenesis in immunocompetent mice, calling into question their use for pancreatic cancer therapy.

Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy

An overview of TAM biology and the current state of nanomedicines that target M2 macrophages in the course of cancer immunotherapy is given, with a specific focus on nanoparticles (NPs).

Autophagy inhibition induces the repolarisation of tumour-associated macrophages and enhances chemosensitivity of laryngeal cancer cells to cisplatin in mice

It seems that CQ-induced M2-to-M1 macrophage repolarisation played an important role in tumour growth inhibition, and the CQ/CDDP combined therapy might have clinical potential in laryngeal cancer treatment.

Macrophage Reprogramming with Anti-miR223-Loaded Artificial Protocells Enhances In Vivo Cancer Therapeutic Potential.

It is shown that phagocytic uptake of anti-miR223-loaded PCs by leukocytes in zebrafish effectively prolongs their pro-inflammatory state by blocking the suppression of pro- inflammatory cytokines, which leads to a reduced cancer burden by driving reduced proliferation and increased cell death of tumor cells.



Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages

It is demonstrated that in vivo TMP195 treatment alters the tumour microenvironment and reduces tumour burden and pulmonary metastases by modulating macrophage phenotypes, and introduces class IIa HDAC inhibition as a means to harness the anti-tumour potential of macrophages to enhance cancer therapy.

Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation

Intratumoral treatment with 3M-052 is a promising approach for the treatment of cancer and a rational strategy and mechanistic understanding is established for combination therapy with intratumoral, tissue-retained TLR7/8 agonist and checkpoint blockade in metastatic cancer.

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

In vivo imaging is used to uncover the fate and activity of aPD-1 mAbs and identify specific Fc/FcγR interactions that can be modulated to improve checkpoint blockade therapy.

Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug

Simultaneous imaging of intratumoral TNP vehicle, its drug payload and single-cell DNA damage response reveals that TAMs serve as a local drug depot that accumulates significant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells.

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

It is demonstrated in a mouse model of pancreatic ductal adenocarcinoma (PDAC) that inhibiting signaling by the myeloid growth factor receptor CSF1R can functionally reprogram macrophage responses that enhance antigen presentation and productive antitumor T-cell responses.

Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging

This method reveals that TAM density was heterogeneous across tumours in the same animal, overall TAM density is different among separate pulmonary tumour models, nanotherapeutic drug delivery correlated with TAM heterogeneity, and successful response to CSF-1R blockade is characterized by enhanced TAM penetration throughout and within tumours.

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

It is shown, to the knowledge for the first time, that ipilimumab can engage ex vivo FcγRIIIA (CD16)-expressing, nonclassical monocytes resulting in ADCC-mediated lysis of regulatory T cells (Tregs).

MerTK inhibition in tumor leukocytes decreases tumor growth and metastasis.

It is demonstrated that MerTK signaling in tumor-associated CD11b+ leukocytes promotes tumor growth by dampening acute inflammatory cytokines while inducing wound healing cytokines, and inhibition of MerTTK in the tumor microenvironment may have clinical benefit, stimulating antitumor immune responses or enhancing immunotherapeutic strategies.

Visualization of IL-12/23p40 In Vivo Reveals Immunostimulatory Dendritic Cell Migrants that Promote Th1 Differentiation1

IL-12p40 is induced in macrophages and dendritic cells (DC) after activation by microbial TLR ligands and cytokines and constitutes a component of IL-12 and IL-23. In an effort to understand the